Player FM - Internet Radio Done Right
Checked 4d ago
تمت الإضافة منذ قبل four أعوام
المحتوى المقدم من Hercules Capital. يتم تحميل جميع محتويات البودكاست بما في ذلك الحلقات والرسومات وأوصاف البودكاست وتقديمها مباشرة بواسطة Hercules Capital أو شريك منصة البودكاست الخاص بهم. إذا كنت تعتقد أن شخصًا ما يستخدم عملك المحمي بحقوق الطبع والنشر دون إذنك، فيمكنك اتباع العملية الموضحة هنا https://ar.player.fm/legal.
Player FM - تطبيق بودكاست
انتقل إلى وضع عدم الاتصال باستخدام تطبيق Player FM !
انتقل إلى وضع عدم الاتصال باستخدام تطبيق Player FM !
المدونة الصوتية تستحق الاستماع
برعاية
A
Advances in Care
![Advances in Care podcast artwork](https://cdn.player.fm/images/55928701/series/ElP1AC184YuHqdZr/32.jpg 32w, https://cdn.player.fm/images/55928701/series/ElP1AC184YuHqdZr/64.jpg 64w, https://cdn.player.fm/images/55928701/series/ElP1AC184YuHqdZr/128.jpg 128w, https://cdn.player.fm/images/55928701/series/ElP1AC184YuHqdZr/256.jpg 256w, https://cdn.player.fm/images/55928701/series/ElP1AC184YuHqdZr/512.jpg 512w)
![Advances in Care podcast artwork](/static/images/64pixel.png)
1 Advancing Cardiology and Heart Surgery Through a History of Collaboration 20:13
20:13
التشغيل لاحقا
التشغيل لاحقا
قوائم
إعجاب
احب20:13![icon](https://imagehost.player.fm/icons/general/red-pin.svg)
On this episode of Advances in Care , host Erin Welsh and Dr. Craig Smith, Chair of the Department of Surgery and Surgeon-in-Chief at NewYork-Presbyterian and Columbia discuss the highlights of Dr. Smith’s 40+ year career as a cardiac surgeon and how the culture of Columbia has been a catalyst for innovation in cardiac care. Dr. Smith describes the excitement of helping to pioneer the institution’s heart transplant program in the 1980s, when it was just one of only three hospitals in the country practicing heart transplantation. Dr. Smith also explains how a unique collaboration with Columbia’s cardiology team led to the first of several groundbreaking trials, called PARTNER (Placement of AoRTic TraNscatheteR Valve), which paved the way for a monumental treatment for aortic stenosis — the most common heart valve disease that is lethal if left untreated. During the trial, Dr. Smith worked closely with Dr. Martin B. Leon, Professor of Medicine at Columbia University Irving Medical Center and Chief Innovation Officer and the Director of the Cardiovascular Data Science Center for the Division of Cardiology. Their findings elevated TAVR, or transcatheter aortic valve replacement, to eventually become the gold-standard for aortic stenosis patients at all levels of illness severity and surgical risk. Today, an experienced team of specialists at Columbia treat TAVR patients with a combination of advancements including advanced replacement valve materials, three-dimensional and ECG imaging, and a personalized approach to cardiac care. Finally, Dr. Smith shares his thoughts on new frontiers of cardiac surgery, like the challenge of repairing the mitral and tricuspid valves, and the promising application of robotic surgery for complex, high-risk operations. He reflects on life after he retires from operating, and shares his observations of how NewYork-Presbyterian and Columbia have evolved in the decades since he began his residency. For more information visit nyp.org/Advances…
#06 – From eBay to Purpose Driven Startups | Servaes Tholen
Manage episode 303482669 series 2940551
المحتوى المقدم من Hercules Capital. يتم تحميل جميع محتويات البودكاست بما في ذلك الحلقات والرسومات وأوصاف البودكاست وتقديمها مباشرة بواسطة Hercules Capital أو شريك منصة البودكاست الخاص بهم. إذا كنت تعتقد أن شخصًا ما يستخدم عملك المحمي بحقوق الطبع والنشر دون إذنك، فيمكنك اتباع العملية الموضحة هنا https://ar.player.fm/legal.
Servaes Tholen (Grove, Thumbtack, UpWork, eBay) is a financial operator with a wealth of experience leading cross-functional teams. After holding various financial positions at eBay, including CFO of the North America business unit, Servaes moved on to work with smaller, dual-purpose startups with social missions. In today’s episode, Servaes joins Catherine Jhung to discuss his transition from eBay to the startup world, his untraditional route from applied physics to finance, how companies like Grove and UpWork are making a difference in the world, and much more.
Topics Include:
Growing up in the Netherlands. How living abroad before moving to the US influenced Servaes and the work he does today. Working as the VP and CFO for eBay’s North America business unit. Key takeaways from his time as a consultant for McKinsey. The marketplace demand for companies with social purposes. The immediacy of climate change, and our social responsibility to respond. Long-term career aspirations. And other topics...
Servaes Tholen is the CFO of Grove Collaborative where he oversees Accounting, FP&A, Corporate Finance and Business Operations. Prior to Grove, Servaes worked at Thumbtack where he served as CFO and COO for over four years. Prior to Thumbtack, Servaes was CFO of Elance and Upwork where he was primarily responsible for Finance, Human Resources, Analytics, and Data Science, before, during, and after the merger between Elance and oDesk that created Upwork. He holds an MSc in Applied Physics from Delft University of Technology, as well as an MBA from INSEAD with a focus on finance.
Want to Connect? Reach out to us online!
Website – https://www.htgc.com/
LinkedIn – https://www.linkedin.com/company/hercules-capital/
Topics Include:
Growing up in the Netherlands. How living abroad before moving to the US influenced Servaes and the work he does today. Working as the VP and CFO for eBay’s North America business unit. Key takeaways from his time as a consultant for McKinsey. The marketplace demand for companies with social purposes. The immediacy of climate change, and our social responsibility to respond. Long-term career aspirations. And other topics...
Servaes Tholen is the CFO of Grove Collaborative where he oversees Accounting, FP&A, Corporate Finance and Business Operations. Prior to Grove, Servaes worked at Thumbtack where he served as CFO and COO for over four years. Prior to Thumbtack, Servaes was CFO of Elance and Upwork where he was primarily responsible for Finance, Human Resources, Analytics, and Data Science, before, during, and after the merger between Elance and oDesk that created Upwork. He holds an MSc in Applied Physics from Delft University of Technology, as well as an MBA from INSEAD with a focus on finance.
Want to Connect? Reach out to us online!
Website – https://www.htgc.com/
LinkedIn – https://www.linkedin.com/company/hercules-capital/
37 حلقات
Manage episode 303482669 series 2940551
المحتوى المقدم من Hercules Capital. يتم تحميل جميع محتويات البودكاست بما في ذلك الحلقات والرسومات وأوصاف البودكاست وتقديمها مباشرة بواسطة Hercules Capital أو شريك منصة البودكاست الخاص بهم. إذا كنت تعتقد أن شخصًا ما يستخدم عملك المحمي بحقوق الطبع والنشر دون إذنك، فيمكنك اتباع العملية الموضحة هنا https://ar.player.fm/legal.
Servaes Tholen (Grove, Thumbtack, UpWork, eBay) is a financial operator with a wealth of experience leading cross-functional teams. After holding various financial positions at eBay, including CFO of the North America business unit, Servaes moved on to work with smaller, dual-purpose startups with social missions. In today’s episode, Servaes joins Catherine Jhung to discuss his transition from eBay to the startup world, his untraditional route from applied physics to finance, how companies like Grove and UpWork are making a difference in the world, and much more.
Topics Include:
Growing up in the Netherlands. How living abroad before moving to the US influenced Servaes and the work he does today. Working as the VP and CFO for eBay’s North America business unit. Key takeaways from his time as a consultant for McKinsey. The marketplace demand for companies with social purposes. The immediacy of climate change, and our social responsibility to respond. Long-term career aspirations. And other topics...
Servaes Tholen is the CFO of Grove Collaborative where he oversees Accounting, FP&A, Corporate Finance and Business Operations. Prior to Grove, Servaes worked at Thumbtack where he served as CFO and COO for over four years. Prior to Thumbtack, Servaes was CFO of Elance and Upwork where he was primarily responsible for Finance, Human Resources, Analytics, and Data Science, before, during, and after the merger between Elance and oDesk that created Upwork. He holds an MSc in Applied Physics from Delft University of Technology, as well as an MBA from INSEAD with a focus on finance.
Want to Connect? Reach out to us online!
Website – https://www.htgc.com/
LinkedIn – https://www.linkedin.com/company/hercules-capital/
Topics Include:
Growing up in the Netherlands. How living abroad before moving to the US influenced Servaes and the work he does today. Working as the VP and CFO for eBay’s North America business unit. Key takeaways from his time as a consultant for McKinsey. The marketplace demand for companies with social purposes. The immediacy of climate change, and our social responsibility to respond. Long-term career aspirations. And other topics...
Servaes Tholen is the CFO of Grove Collaborative where he oversees Accounting, FP&A, Corporate Finance and Business Operations. Prior to Grove, Servaes worked at Thumbtack where he served as CFO and COO for over four years. Prior to Thumbtack, Servaes was CFO of Elance and Upwork where he was primarily responsible for Finance, Human Resources, Analytics, and Data Science, before, during, and after the merger between Elance and oDesk that created Upwork. He holds an MSc in Applied Physics from Delft University of Technology, as well as an MBA from INSEAD with a focus on finance.
Want to Connect? Reach out to us online!
Website – https://www.htgc.com/
LinkedIn – https://www.linkedin.com/company/hercules-capital/
37 حلقات
كل الحلقات
×![Artwork](/static/images/128pixel.png)
1 #36 - Building the Super App for Mealtime: Wonder's Recipe for Disrupting Meal Delivery | Kelley Morrell 46:16
46:16
التشغيل لاحقا
التشغيل لاحقا
قوائم
إعجاب
احب46:16![icon](https://imagehost.player.fm/icons/general/red-pin.svg)
Share your thoughts with us! The food delivery landscape is changing. As consumer demands grow more sophisticated, companies must innovate—balancing speed, quality, and personalization to stand out in a saturated market. But can convenience and quality coexist in this fast-paced industry? Is there a way to truly personalize the dining experience while catering to the individual needs of each customer? Kelley Morell is the CFO of Wonder, a rising "super app" for mealtime. In this episode, Hercules Capital's Ruslan Sergeyev speaks with Kelley about her career journey, transitioning from an accomplished investor at Blackstone to leading the financial strategy of this startup. She reveals the unique approach Wonder is taking to conquer the food tech space, combining a multi-faceted platform with strategic acquisitions to offer an unparalleled consumer experience. Topics Include: Wonder's evolution from mobile kitchens to a hybrid brick-and-mortar and delivery model The challenges of competing in a crowded market and differentiating Wonder's offering The role of AI in personalizing food recommendations and creating a seamless user experience Building a strong team and culture to support rapid growth Wonder's future plans for national expansion and a potential IPO And other topics… Kelley Morell is the CFO of Wonder, a rapidly growing food tech company aiming to become the "super app" for mealtime. With extensive experience in both investing and operating, Kelley provides a valuable perspective on building a successful business in a dynamic industry. Her insights into the future of food, the power of technology, and the importance of a strong team offer inspiration for anyone looking to disrupt the status quo.…
![Artwork](/static/images/128pixel.png)
1 #35 - Revolutionizing Compliance: AI's Role in Modern Finance | Erkin Adylov 35:51
35:51
التشغيل لاحقا
التشغيل لاحقا
قوائم
إعجاب
احب35:51![icon](https://imagehost.player.fm/icons/general/red-pin.svg)
Share your thoughts with us! The financial services industry faces increasing pressure to combat financial crime and comply with evolving regulations. The old way of handling compliance—mostly through manual work—isn't cutting it anymore given how complex and fast-moving today's financial world is. This is where AI comes in, offering a powerful new way to strengthen compliance and protect market integrity. In this episode, Hercules Capital's Catherine Jhung speaks with Erkin Adylov, founder of Behavox and former hedge fund manager. He walks us through his career shift from managing investments to launching his own company. He explains why he started Behavox, which uses AI to help financial institutions stay compliant – a solution born from his firsthand experience seeing the limitations of traditional compliance methods. Topics Include: The rise of AI in financial services compliance How Behavox uses AI to spot financial crime Why AI makes financial monitoring better Strategies for retraining compliance teams in the age of AI Behavox’s future plans for expanding into transaction screening and policy management And other topics… Erkin Adylov is the founder and CEO of Behavox, a leading provider of AI-enabled compliance solutions for the financial services industry. With a deep understanding of the complexities of financial markets and the evolving regulatory landscape, Erkin has led Behavox to become a trusted partner for institutions seeking to enhance their compliance programs and protect the integrity of capital markets.…
![Artwork](/static/images/128pixel.png)
1 #34 - The Evolution of Biotech Deals: From Pharma Consolidation to Innovation | Stephen Sands 47:03
47:03
التشغيل لاحقا
التشغيل لاحقا
قوائم
إعجاب
احب47:03![icon](https://imagehost.player.fm/icons/general/red-pin.svg)
Share your thoughts with us! The biotech and pharma industries are rapidly evolving, with mergers and acquisitions driving innovation and growth. As market demands shift, these deals reshape strategies, bolster R&D, and bring groundbreaking therapies to healthcare. With over 35 years of experience, Stephen Sands has guided high-impact transactions that have shaped the biotech and pharma landscape. In this episode, Janice Bourque speaks with Stephen about his journey from bioengineer to healthcare M&A leader. They examine the forces that drive today’s major deals, from global expansion to complex valuation challenges, and the strategies that ensure success in a competitive market. Topics Include: Key trends and strategies in biotech/pharma M&A Challenges in valuing early-stage biotech companies Pharma’s evolving role in funding and scaling biotech innovations Future outlook for healthcare partnerships and acquisitions Stephen’s insights on the future of healthcare M&A And other topics… Stephen Sands is a Senior Advisor in Lazard’s Global Healthcare Group with a distinguished career in healthcare M&A. Known for his expertise in biotech and pharma, Stephen has led some of the industry's most transformative transactions, helping to drive strategic growth and innovation in the healthcare sector.…
![Artwork](/static/images/128pixel.png)
1 #33 - How Corporate Venture Capital is Driving Healthcare Innovation | Vijay Patel 57:04
57:04
التشغيل لاحقا
التشغيل لاحقا
قوائم
إعجاب
احب57:04![icon](https://imagehost.player.fm/icons/general/red-pin.svg)
Share your thoughts with us! Vijay Patel is an institutional investor turned corporate venture capitalist. He has spent the last decade at the intersection of finance and healthcare, changing the way CVS Health approaches innovation and strategic investments. His journey from traditional venture capital to leading CVS Health® Ventures has positioned him as a thought leader in corporate venture capital and healthcare innovation. In this episode, Janice Bourque is joined by Vijay Patel to discuss his path from institutional investor to Managing Partner of CVS Health Ventures. They discuss the creation and growth of CVS Ventures, highlighting Vijay's approach to fostering innovation and driving strategic value in the healthcare ecosystem. Topics Include: Vijay's transition from institutional investing to corporate venture capital The founding story of CVS Ventures and its impact on healthcare innovation CVS Ventures’ investment strategies and focus areas The role of corporate venture capital in shaping the future of healthcare Vijay's vision for the future of healthcare technology and innovation And other topics... Vijay Patel is the managing partner and co-founder of CVS Health Ventures and vice president of enterprise business development for CVS Health. Patel founded the CVS® Digital Leadership Program and has played a key role in developing strategic partnerships with digital health companies. Patel holds a bachelor's degree from the University of Pennsylvania's Jerome Fisher Program in Management and Technology and an MBA from the MIT Sloan School of Management.…
![Artwork](/static/images/128pixel.png)
1 #32 - The Future of Drug Affordability and Access | Peter Kolchinsky 56:46
56:46
التشغيل لاحقا
التشغيل لاحقا
قوائم
إعجاب
احب56:46![icon](https://imagehost.player.fm/icons/general/red-pin.svg)
Share your thoughts with us! In an era where breakthrough innovations coexist with concerns over drug affordability, Peter Kolchinsky, founder and Managing Partner at healthcare and life sciences investment manager RA Capital, joins us to shed light on the factors and paths forward. Hercules Capital's Janice Bourque engages with Peter on his No Patient Left Behind initiative, a non-profit dedicated to making medicines affordable for everyone in America. Topics Include: Overview of the "No Patient Left Behind" movement and its objectives Examining communication challenges within the drug industry The pivotal role of insurance in enabling patient access and affordability Strategies to maintain support for innovation amid pricing concerns Potential solutions to bridge the gap between innovation and affordability Peter Kolchinsky, PhD is a founder and Managing Partner at RA Capital Management and author of The Great American Drug Deal . Peter is an active investor in and board member of publicly- and privately-held companies developing drugs, medical devices, diagnostics, and research tools. He served on the Board of Global Science and Technology for the National Academy of Sciences, is the author of The Entrepreneur’s Guide to a Biotech Startup , and frequently writes and speaks on the future of biotechnology innovation. Peter founded and serves as a Director of No Patient Left Behind, a non-profit advocate for healthcare reforms that would make today's medicines affordable to patients and promote the innovation that gives all of us hope for tomorrow. He holds a BA from Cornell University and a PhD in Virology from Harvard University.…
![Artwork](/static/images/128pixel.png)
1 #31 - Dynamics of Venture Debt: Balancing Legal and Business Objectives | David Ephraim 26:57
26:57
التشغيل لاحقا
التشغيل لاحقا
قوائم
إعجاب
احب26:57![icon](https://imagehost.player.fm/icons/general/red-pin.svg)
Share your thoughts with us! Navigating the intricate world of venture debt requires a deep understanding of both the legal landscape and financial imperatives. David Ephraim from Morrison & Foerster brings over two decades of experience to the table, making him a leading authority on structuring deals that align legal precision with business innovation. This episode, hosted by Janice Bourque from Hercules Capital, engages David Ephraim in a discussion about the nuances of venture debt, including how negotiations are framed, the roles of various stakeholders, and the essential strategies for overcoming common challenges. David also provides forward-looking insights into how the field might evolve in the coming years. Topics include: Overview of venture debt and its importance Detailed look at negotiation processes in venture debt How legal and business issues intertwine in these negotiations The importance of strategic foresight in financial planning David’s perspectives on the future of venture debt David Ephraim is the co-chair of Morrison Foerster’s Transactions Department and managing partner of their Boston office. He specializes in various aspects of secured lending, including venture debt, fund finance, and cross-border financing transactions. David's expertise ensures sophisticated solutions for banks, institutional lenders, and private funds, making him a pivotal figure in the financial industry. Join us on today’s episode, where David Ephraim’s expertise offers invaluable perspectives on the nuanced processes that underpin successful venture debt strategies, providing our listeners with guidance for navigating these essential financial instruments.…
![Artwork](/static/images/128pixel.png)
1 #30 – Rise of the Business Operator: Cultivating the Ultimate Community of Tech Leaders | Casey Woo 50:50
50:50
التشغيل لاحقا
التشغيل لاحقا
قوائم
إعجاب
احب50:50![icon](https://imagehost.player.fm/icons/general/red-pin.svg)
Share your thoughts with us! Public market investor turned tech visionary, Casey Woo, has spent the last two decades at the forefront of technology and finance, revolutionizing the way high-growth startups approach operations and strategy. His journey from analyzing markets on Wall Street to leading Operators Guild and FOG Ventures has positioned him as a thought leader at the intersection of technology, finance, and community building. In this episode, Catherine Jhung is joined by Casey Woo to discuss his unique path from public market investor to influential COO/CFO in the tech industry. They discuss the creation and growth of Operators Guild and FOG Ventures, highlighting Casey's approach to fostering community and driving innovation in the startup ecosystem. Topics Include: -Casey's transition from public market investor to tech COO/CFO -The founding story of Operators Guild and its impact on the tech community -Inside FOG Ventures: Strategy and vision for tech startups -The role of community in the success of tech and finance ventures -Navigating high-growth challenges in the startup world -Casey's vision for the future of technology and finance -And other topics… Casey Woo is the founder of Operators Guild, the premier community and ecosystem for finance and operational professionals at high growth companies, and its associated investing arm, FOG Ventures. He has two decades of experience as a proven, serial COO/CFO in high-growth technology companies, most recently as the CFO of property tech company Landing. Casey started his career as a public market investor focused on the consumer/retail, media, industrials, technology and healthcare sectors. His expertise in blending strategic finance with operational excellence has made him a pivotal figure in shaping the landscape of technology startups.…
![Artwork](/static/images/128pixel.png)
1 #29 – Endpoints News: Predictions for Biotech in 2024 and Beyond | John Carroll 46:00
46:00
التشغيل لاحقا
التشغيل لاحقا
قوائم
إعجاب
احب46:00![icon](https://imagehost.player.fm/icons/general/red-pin.svg)
Share your thoughts with us! In the aftermath of the 2020 biotech surge and its subsequent contraction in 2022, the biotech industry has been characterized by significant volatility. There were 21 biotechnology IPOs in 2022, a notable decrease from the record-breaking 104 IPOs in 2021. To review the highs and lows of 2023 and explore what lies ahead in 2024, distinguished biotech analyst and co-founder of Endpoints News John Carroll joins Hercules Capital's Janice Bourque . Carroll brings 45 years of award-winning journalism, and a specialization in biopharma spanning over two decades to discuss the biggest pharma deals and surprises of 2023, the impact of AI on drug development, the future of biotech in Asia, and much more. Topics Include: The biggest pharma deals and surprises of 2023 AI’s impact on drug development Whether or not the Inflation Reduction Act will impact pricing John’s major lessons from 2023 The future of biotech in Asia The greatest concerns for the biotech industry going into 2024 John’s hopes for the industry in the new year And other topics… ------------------ John D. Carroll is a biotech analyst and writer with decades of prize-winning experience in journalism. A co-founder of Endpoints News , he has covered biopharma for the past 15 years. Carroll has been quoted by The New York Times , The New Yorker , Financial Times , The Times of London and more. He’s also keynoted at biotech gatherings around the world and addressed student audiences at MIT and Harvard. Carroll has contributed stories from Central America and Ireland to the Dallas Morning News and Time and wrote for the Houston Press . He spent 6 years as editor and publisher of the Dallas Business Journal , was publisher of Texas Business and early in his career was part of a Pulitzer Prize-winning team of reporters and editors at the Kansas City Star & Times . Resources Mentioned: Endpoints News: https://endpts.com/ Connect with John: LinkedIn: https://www.linkedin.com/in/john-carroll-884aa410/…
![Artwork](/static/images/128pixel.png)
1 #28 – The Non-CFO, CFO: Executive Leadership, Acquisitions, and Serving 350 Million Users as Fandom’s CFO | Ed Lu 56:53
56:53
التشغيل لاحقا
التشغيل لاحقا
قوائم
إعجاب
احب56:53![icon](https://imagehost.player.fm/icons/general/red-pin.svg)
Share your thoughts with us! The gaming and platform industries are dynamic sectors at the intersection of technology and entertainment, constantly evolving to meet the demands of a global audience. In 2022, the revenue from the worldwide gaming market was approximately $347 billion. Ed Lu, a seasoned executive with 23 years of financial and operational experience, has played a pivotal role in this landscape, dedicating thirteen years as the CFO at online gaming and platform companies. Ed is the current Chief Financial Officer at Fandom, the world’s largest gaming and entertainment community platform. In this episode, Hercules Capital's Lesya Kulchenko and Ed Lu discuss Ed’s CFO experience within gaming and platform companies, top advice for new founders and aspiring CFOs in today’s business landscape, choosing between building, buying, and partnering, the key factors for successful acquisitions, when to pursue bargain opportunities, and much more. Topics Include: Ed’s top priorities as a CFO in today’s business landscape Essential advice for emerging founders and aspiring CFOs Core values that led Ed to leadership The advice Ed gratefully avoided Choosing between building, buying, and partnering Key factors for successful acquisitions When companies should pursue bargain opportunities Factors outside of work that shape Ed as the “non-CFO CFO” And other topics… ---------- Ed Lu is a seasoned executive with 23 years of financial and operational experience and thirteen years as CFO at online gaming and platform companies. He is the current Chief Financial Officer at Fandom, the world’s largest gaming and entertainment community platform. During his tenure, Fandom has grown revenue by more than 3x, acquired three companies, and doubled its employee base to 500. Before joining Fandom, Ed served as the CFO for Outpost Games and Machine Zone. His tenure at Machine Zone involved raising over $800 million in combined financings, overseeing revenue growth from $8 million to $1.7 billion, and scaling the company from 30 to 1000+ employees. In his free time, he also enjoys serving as a strategic advisor for other digital gaming companies. Resources Mentioned: “Top 10 Start-Up Tips for Founders,” by Ed Lu: https://www.linkedin.com/feed/update/urn:li:activity:6998677341623267328/…
![Artwork](/static/images/128pixel.png)
1 #27 – The Evolution of Biotech: Lessons From 35 Years of Early Stage Investing | Terry McGuire 34:29
34:29
التشغيل لاحقا
التشغيل لاحقا
قوائم
إعجاب
احب34:29![icon](https://imagehost.player.fm/icons/general/red-pin.svg)
Share your thoughts with us! Healthcare and biotech venture capital plays a critical role in funding innovative medical technologies, drug development, and life-saving therapies. These investments drive advancements in healthcare, transforming science into products that improve global patient outcomes. Terry McGuire is a founding partner of Polaris Partners, with over 35 years of early-stage investing experience in medical and information technology companies. As a venture capitalist, Terry has invested in more than 80 companies that have raised over $7 billion in equity and corporate capital. In this episode, Hercules Capital’s Janice Bourque and Terry McGuire discuss Terry’s trajectory from generalist to distinguished expert in healthcare and biotech venture capital, strategies to find the right scientists and product, Terry’s biggest lessons in raises, limited partnerships and investor relationships, and much more. Topics Include: Terry’s path from generalist to venture capitalist Strategies to find the right scientists 3 traits that can turn a scientist into an effective CEO How to turn science into a product The emerging technologies to look out for Strengths and weaknesses of the industry Terry’s biggest lessons from the evolution of raises, limited partnerships, and investor relationships And other topics… Terry McGuire is a founding partner of Polaris Partners, with over 35 years of early-stage investing experience in medical and information technology companies. As a venture capitalist, Terry has invested in more than 80 companies that have raised over $7 billion in equity and corporate capital. He also co-founded three companies: Inspire, AIR, and MicroCHIPS. Companies Terry has supported have touched more than 60 million patients and directly saved over 400,000 lives. Terry has been listed as one of Scientific American’s Worldview 100, Forbes’ Top Life Sciences Investors, and Forbes’ Midas 100 List of Top Tech Investors, among others. He is the chairman of the Global Venture Capital Congress, serves on several public and private boards of directors, and is the recipient of various awards, including the Albert Einstein Award for Outstanding Achievement in the Life Sciences awarded by Harvard and the City of Jerusalem.…
![Artwork](/static/images/128pixel.png)
1 #26 – Biotech and the Public: Breakthroughs, Drug Prices, and Public Relations | Rich Aldrich 40:59
40:59
التشغيل لاحقا
التشغيل لاحقا
قوائم
إعجاب
احب40:59![icon](https://imagehost.player.fm/icons/general/red-pin.svg)
Share your thoughts with us! In the dynamic field of life sciences, skillful operators ensure the efficient development of medical innovations, while insightful investors provide crucial capital and strategic guidance. Rich Aldrich's 30+ year career uniquely bridges both sides, having played key roles in founding and managing successful ventures in the industry. Rich Aldrich is a co-founder and partner at Longwood Fund. Before Longwood, he founded RA Capital Management and has been instrumental in co-founding and contributing to the growth of notable biotech companies, including Sirtris Pharmaceuticals, Concert Pharmaceuticals, and Vertex Pharmaceuticals, among others. In this episode, Hercules Capital’s Janice Bourque and Rich Aldrich discuss key lessons in operations and investment, the advantages of public investing, the attributes of a strong management team, Rich’s reflections on the industry and much more. Topics include: Transitioning from operations to investing Rich’s key lessons from public investments The advantages of public investing Attributes of a strong management team Current areas of scientific interest for Rich Emerging challenges in life sciences Deciding whether or not to commercialize Rich’s reflections on the industry’s evolution And other topics… Rich Aldrich is a co-founder and partner of Longwood Fund, an early-stage life science venture firm. With over 30 years of experience in the life sciences space, he has co-founded and helped build several biotech companies including Sirtris Pharmaceuticals, Concert Pharmaceuticals, and Vertex Pharmaceuticals, among others. Before the Longwood Fund, Rich founded RA Capital Management, a life sciences investment fund with an AUM of over $9 billion. Rich received his undergraduate degree from Boston College and an MBA from the Amos Tuck School at Dartmouth. He currently serves as a Director of Longwood portfolio companies Axial, Sitryx Therapeutics, and Colorescience.…
![Artwork](/static/images/128pixel.png)
1 #25 – From Physician to Founder: Scaling Iora Health to a $2 Billion Exit | Rushika Fernandopulle 33:19
33:19
التشغيل لاحقا
التشغيل لاحقا
قوائم
إعجاب
احب33:19![icon](https://imagehost.player.fm/icons/general/red-pin.svg)
Share your thoughts with us! The healthcare space has long been a transactional one, seeing patients as numbers instead of human relationships. In 2004, Dr. Rushika Fernandopulle began to challenge the status quo and create an entirely new model of care delivery that finally put patients at the center of healthcare. Rushika Fernandopulle is the co-founder and former CEO of Iora Health, a value-based primary care group based in Boston that was acquired by One Medical in 2021, where he served as Chief Innovation Officer. One Medical was acquired by Amazon earlier this year for close to $4 billion. Rushika currently serves on the staff at the Massachusetts General Hospital, on the faculty of Harvard Medical School, and on the boards of Families USA and the Schwartz Center for Compassionate Care. In this episode, Hercules Capital’s Katie Segien is joined by Rushika Fernandopulle to discuss how he created a new delivery model for medicine, Iora Health’s business model evolution, going from bootstrapping to six rounds of funding, and other topics. Topics Include: Rushika’s mission and experience in transforming healthcare How he created a new delivery model for medicine Iora Health’s business model evolution Going from bootstrapping to six rounds of funding Rushika’s process for building an optimal team Advice for entrepreneurs who are struggling to raise capital And other topics… Dr. Rushika Fernandopulle is a practicing physician who has spent decades improving the quality of healthcare delivered to patients. He was co-founder and CEO of Iora Health, a value-based primary care group based in Boston that delivers better quality, lower costs, and improved satisfaction for both patients and providers. Iora was acquired by One Medical in 2021 for over $2 billion, which went on to be acquired by Amazon earlier this year for close to $4 billion. Rushika was the first Executive Director of the Harvard Interfaculty Program for Health Systems Improvement and Managing Director of the Clinical Initiatives Center at the Advisory Board Company. He serves on the staff at the Massachusetts General Hospital, on the faculty of Harvard Medical School, and on the boards of Families USA and the Schwartz Center for Compassionate Care.…
![Artwork](/static/images/128pixel.png)
1 #24 – Scaling up in Biotech, Raising $300M for a Single Pharma Product | Mark Hahn 31:57
31:57
التشغيل لاحقا
التشغيل لاحقا
قوائم
إعجاب
احب31:57![icon](https://imagehost.player.fm/icons/general/red-pin.svg)
Share your thoughts with us! Successful biotech companies require a capable CFO to guide the company through conducting clinical trials, securing regulatory approvals, establishing scalable production, and adeptly conveying value to healthcare stakeholders. Mark Hahn is a seasoned executive with over 25 years of CFO experience. He is currently the CFO of Verona Pharma, a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of chronic respiratory diseases with significant unmet medical needs. In this episode, Hercules Capital’s Janice Bourque is joined by Hahn to discuss his experience as CFO of Verona, Dova, and Cempra, the intricacies of single-asset companies, preparing a company for FDA approval and commercialization, identifying a successful launch, and much more. Topics Include: Mark’s experience as CFO of Verona, Dova, and Cempra The intricacies of single-asset companies and the challenges when raising capital The steps a CFO should take when preparing for FDA approval and commercialization What biotech companies should focus on before presenting to the FDA How to know when you’ve had a successful launch Mark’s experience as a CFO with a late-stage asset And other topics… Mark Hahn is a seasoned CFO with over 25 years of experience. He joined Verona Pharma as CFO in 2020. Prior to Verona, Hahn served as CFO of Dova Pharmaceuticals through its 2019 acquisition by Swedish Orphan Biovitrum for $915 million. There, he was instrumental in raising capital and launching the company’s first commercial product. Prior to Dova, Hahn was CFO of Cempra, where he led the company’s IPO and several subsequent follow-on offerings until the company’s acquisition by Melinta Therapeutics in 2017. Earlier, Hahn was the CFO of several other public and private companies. Hahn began his career at Ernst & Young. He received a Bachelor of Business Administration degree in accounting and finance from the University of Wisconsin-Milwaukee and is a certified public accountant in Maryland and North Carolina.…
![Artwork](/static/images/128pixel.png)
1 #23 – From $3B to $29B in 7 Years, the Boom in Healthcare Technology Investment | Michael Greeley 28:48
28:48
التشغيل لاحقا
التشغيل لاحقا
قوائم
إعجاب
احب28:48![icon](https://imagehost.player.fm/icons/general/red-pin.svg)
Share your thoughts with us! The healthcare technology sector has witnessed astonishing growth in investments, skyrocketing from $3 billion pre-pandemic to $29 billion in 2021. Michael Greeley brings invaluable insights to the show as the co-founder and general partner of Flare Capital Partners, a pioneering venture capital firm dedicated to healthcare technology. Before Flare, Greeley was the founding general partner of Flybridge Capital Partners. Earlier in his career, he was with Polaris Partners, and also held positions at GCC Investments, Wasserstein Perella & Co., and Morgan Stanley & Co. In this episode, Hercules Capital’s Katie Segien is joined by Michael Greeley to discuss his experience as an early pioneer in health tech investments, the remarkable growth and challenges of healthcare technology, the impact of AI on healthcare programs and services, and much more. Topics Include: Michael’s experience as an early pioneer in health tech investments Liquidity and scaling challenges for healthcare tech companies How to create a more sustainable business model in this space What Michael looks for when building out his portfolio companies AI’s impact on healthcare programs and services The Flare Scholars program Future challenges and possibilities in the healthcare sector And other topics… Michael Greeley is a co-founder and general partner at Flare Capital Partners. Before co-founding Flare in 2014, he focused on emerging growth company financings as the founding general partner of Flybridge Capital Partners. Earlier, he held positions with Polaris Partners, GCC Investments, Wasserstein Perella & Co., and Morgan Stanley & Co. Greeley sits on dozens of boards and authors the blog On the Flying Bridge . Greeley received a BA with honors in chemistry from Williams College and an MBA from Harvard Business School. While he considers himself a New Yorker, he grew up in Hong Kong and currently resides in Boston. Resources Mentioned: Flare Capital Partners: https://www.flarecapital.com/ Michael Greeley’s blog: https://ontheflyingbridge.wordpress.com/ Flare Capital Scholars Program: https://www.flarecapital.com/flare-capital-scholar-application…
![Artwork](/static/images/128pixel.png)
1 #22 – Women’s Health: An Overlooked Market That’s Hot for Investors in 2023 | Elizabeth Bailey 32:39
32:39
التشغيل لاحقا
التشغيل لاحقا
قوائم
إعجاب
احب32:39![icon](https://imagehost.player.fm/icons/general/red-pin.svg)
Share your thoughts with us! Elizabeth Bailey has more than 20 years of experience supporting early-stage startups as a venture capitalist. Today, she is a founding member at RH Capital where she serves as the fund's Managing Director. RH Capital is a women-led, impact venture capital fund that strategically invests in early-stage startups dedicated to revolutionizing women's health. In this episode, Elizabeth joins Hercules Capital’s Janice Bourque to discuss the origin, strategies, and portfolio of RH Capital. They discuss how female founders are changing the landscape in the women’s health space with support from venture capitalists. Topics Include: - High return opportunities for investors in the women’s health space - How venture capital can improve health outcomes for underserved groups - The origin, strategies, and portfolio of RH Capital - Collaboration opportunities for strategic investors, startups, and venture funds - Conducting thorough due diligence when evaluating companies - And other topics… Elizabeth Bailey is the Managing Director and founding team member at RH Capital, a women-led impact venture capital fund for early-stage startups focused on health equity and revolutionizing women’s health. RH Capital leverages investment capital to address health disparities, focusing on biotech, devices, diagnostics, digital health, and services. Elizabeth has over 20 years of experience in venture capital and supporting early-stage companies. Before joining RH Capital, Elizabeth served as the Founding Director of the Consortium for Affordable Medical Technologies at Massachusetts General Hospital and Investment Partner at Commons Capital, one of the first impact investment funds. Elizabeth holds a Master’s from Harvard Kennedy School and a BA from Brown University. Resources Mentioned: RH Capital: https://www.rh.capital/ Tara Health Foundation: http://tarahealthfoundation.org/ May: https://www.getmay.com/ Radiant Oximetry: http://www.radianoximetry.com/…
مرحبًا بك في مشغل أف ام!
يقوم برنامج مشغل أف أم بمسح الويب للحصول على بودكاست عالية الجودة لتستمتع بها الآن. إنه أفضل تطبيق بودكاست ويعمل على أجهزة اندرويد والأيفون والويب. قم بالتسجيل لمزامنة الاشتراكات عبر الأجهزة.